# HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications

> **NCT02775227** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Helsinki University Central Hospital** · enrollment: 126 (actual)

## Conditions studied

- Pancreatic Fistula
- Pancreatic Neoplasms

## Interventions

- **DRUG:** Hydrocortisone
- **DRUG:** Pasireotide

## Key facts

- **NCT ID:** NCT02775227
- **Lead sponsor:** Helsinki University Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-05
- **Primary completion:** 2019-01
- **Final completion:** 2029-12
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2020-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02775227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02775227, "HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02775227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*